Cover Image

Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies

Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted recepto...

Full description

Saved in:
Bibliographic Details
Main Authors: Podar, Klaus (Author) , Anderson, Kenneth C. (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Current cancer drug targets
Year: 2011, Volume: 11, Issue: 9, Pages: 1005-1024
ISSN:1873-5576
DOI:10.2174/156800911798073113
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2174/156800911798073113
Get full text
Author Notes:K. Podar and K.C. Anderson

MARC

LEADER 00000caa a2200000 c 4500
001 183000512X
003 DE-627
005 20230710095252.0
007 cr uuu---uuuuu
008 221223s2011 xx |||||o 00| ||eng c
024 7 |a 10.2174/156800911798073113  |2 doi 
035 |a (DE-627)183000512X 
035 |a (DE-599)KXP183000512X 
035 |a (OCoLC)1389738557 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Podar, Klaus  |e VerfasserIn  |0 (DE-588)1058672169  |0 (DE-627)797396594  |0 (DE-576)414826795  |4 aut 
245 1 0 |a Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies  |c K. Podar and K.C. Anderson 
264 1 |c 2011 
300 |a 20 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 23.12.2022 
520 |a Research on the formation of new blood vessels (angiogenesis) in general and vascular endothelial growth factor (VEGF) in particular is a major focus in biomedicine and has led to the clinical approval of the monoclonal anti- VEGF antibody bevazicumab; and the second-generation multitargeted receptor kinase inhibitors (RTKIs) sorafenib, sunitinib, and pazopanib. Although these agents show significant preclinical and clinical anti-cancer activity, they prolong overall survival of cancer patients for only months, followed by a restoration of tumor growth and progression. Therefore, there is a clear need to increase our understanding of tumor angiogenesis and the development of resistance. In this review we discuss up-to-date knowledge on mechanisms of tumor angiogenesis, and summarize preclinical and clinical data on existing and potential future anti-angiogenic agents and treatment strategies for Multiple Myeloma (MM) and other hematologic and solid malignancies. 
650 4 |a Angiogenesis Inhibitors 
650 4 |a Antibodies, Monoclonal 
650 4 |a Benzenesulfonates 
650 4 |a Hematologic Neoplasms 
650 4 |a Humans 
650 4 |a Indoles 
650 4 |a Multiple Myeloma 
650 4 |a Neovascularization, Pathologic 
650 4 |a Niacinamide 
650 4 |a Phenylurea Compounds 
650 4 |a Phthalazines 
650 4 |a Protein Kinase Inhibitors 
650 4 |a Protein-Tyrosine Kinases 
650 4 |a Pyridines 
650 4 |a Pyrroles 
650 4 |a Receptors, Vascular Endothelial Growth Factor 
650 4 |a Signal Transduction 
650 4 |a Sorafenib 
650 4 |a Sunitinib 
650 4 |a Thalidomide 
650 4 |a Vascular Endothelial Growth Factor A 
650 4 |a Wnt Signaling Pathway 
700 1 |a Anderson, Kenneth C.  |e VerfasserIn  |0 (DE-588)136657109  |0 (DE-627)585450668  |0 (DE-576)172453887  |4 aut 
773 0 8 |i Enthalten in  |t Current cancer drug targets  |d Hilversum [u.a.] : Bentham Science Publ., 2001  |g 11(2011), 9, Seite 1005-1024  |h Online-Ressource  |w (DE-627)362755582  |w (DE-600)2099324-9  |w (DE-576)273874209  |x 1873-5576  |7 nnas  |a Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies 
773 1 8 |g volume:11  |g year:2011  |g number:9  |g pages:1005-1024  |g extent:20  |a Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies 
856 4 0 |u https://doi.org/10.2174/156800911798073113  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221223 
993 |a Article 
994 |a 2011 
998 |g 1058672169  |a Podar, Klaus  |m 1058672169:Podar, Klaus  |d 910000  |d 910100  |e 910000PP1058672169  |e 910100PP1058672169  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN183000512X  |e 4240929245 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"2011"}],"id":{"eki":["183000512X"],"doi":["10.2174/156800911798073113"]},"name":{"displayForm":["K. Podar and K.C. Anderson"]},"physDesc":[{"extent":"20 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Hilversum [u.a.]","dateIssuedKey":"2001","publisher":"Bentham Science Publ.","dateIssuedDisp":"2001-"}],"id":{"eki":["362755582"],"zdb":["2099324-9"],"issn":["1873-5576"]},"disp":"Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignanciesCurrent cancer drug targets","note":["Gesehen am 09.04.24"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"recId":"362755582","pubHistory":["1.2001 -"],"part":{"extent":"20","volume":"11","text":"11(2011), 9, Seite 1005-1024","issue":"9","pages":"1005-1024","year":"2011"},"title":[{"title_sort":"Current cancer drug targets","title":"Current cancer drug targets"}]}],"title":[{"title":"Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies","title_sort":"Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies"}],"person":[{"roleDisplay":"VerfasserIn","display":"Podar, Klaus","role":"aut","family":"Podar","given":"Klaus"},{"family":"Anderson","given":"Kenneth C.","display":"Anderson, Kenneth C.","roleDisplay":"VerfasserIn","role":"aut"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 23.12.2022"],"language":["eng"],"recId":"183000512X"} 
SRT |a PODARKLAUSEMERGINGTH2011 

Similar Items